Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-005325
Filing Date
2025-02-24
Accepted
2025-02-24 17:52:59
Documents
1
Period of Report
2025-02-24

Document Format Files

Seq Description Document Type Size
1 form4-02242025_100255.html 4  
1 form4-02242025_100255.xml 4 4163
  Complete submission text file 0001415889-25-005325.txt   5645
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Issuer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O HATTERAS VENTURE PARTNERS III, LP 280 S. MANGUM ST., SUITE 350 DURHAM NC 27701
Business Address
Thorp Clay (Reporting) CIK: 0001592380 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37783 | Film No.: 25658478